Evidence map›Paper›PMID 41402342›Full record

ReviewNPJ breast cancer2025

Computational pathology in breast cancer: optimizing molecular prediction through task-oriented AI models.

Chiara Frascarelli, Konstantinos Venetis, Antonio Marra, Alberto Concardi, Marianna D'Ercole, Elisa Mangione, Mariachiara Negrelli, Francesca Maria Porta, Sakshi Keswani, Giuseppe Curigliano and 2 more

Abstract readReview
In one paragraph

Review in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chiara Frascarelli *Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Konstantinos Venetis *Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Antonio MarraDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Alberto ConcardiDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Marianna D'ErcoleDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Elisa MangioneDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Mariachiara NegrelliDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Francesca Maria PortaDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Sakshi KeswaniDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Giuseppe CuriglianoDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Elena Guerini-RoccoDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Nicola FuscoDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy. nicola.fusco@ieo.it.ORCID http://orcid.org/0000-0002-9101-9131

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The integration of artificial intelligence (AI) in breast cancer pathology has been driven by the promise of "big data"-based foundation models: large deep learning systems deriving diagnostic and prognostic insights from digitized whole slide images (WSIs). Yet, despite progress in computational power and architectures, these models face obvious barriers to clinical use, including poor workflow integration, limited explainability, and reduced generalizability across diverse clinical settings. This article examines the opportunities provided by small, task-oriented AI models designed to predict clinically relevant molecular features in breast cancer, such as hormone receptors (HRs), HER2, Ki-67, BRCA-related status, and somatic mutations directly from WSIs. To overcome foundation model constraints, approaches like model distillation, weak supervision, and modular training are critically examined. Progress now depends on high-quality datasets, rigorous multi-institutional validation, and collaboration between computational scientists, clinicians, and regulators to deliver explainable, clinically actionable innovations in breast cancer.

Identifiers

PMID41402342
PMCPMC12708783

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.